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ABSTRACT
Interactions of GABA, bicuculline methochloride and diazepam with 
[3H]TBOB binding to rat brain membranes were evaluated in vitro.
GABA displaced [3H]TBOB binding with and IC50 of 4 (iM and a slope 
factor near unity. The competitive GABA antagonist bicuculline methochloride 
shifted the displacement curve of GABA parallelly to the right, indicating fha:t 
the interaction of GABA with [3H]TBOB binding is of an allosteric nature.
In the presence of GABA, diazepam displaced the binding of [3H]TBOB
I
according to a two-site model: a high affinity site with an IC50 of about 50 nM
, *
and a lower affinity site with an IC50 of about 30 |oM. Bicuculline
I ,  .
methochloride abolished the nanomolar displacement by diazepam and in­
creased the micromolar IC50 value. These results indicate that the interaction of 
the high affinity diazepam site with the [3H]TBOB binding site is totally 
GABA dependent and that the low affinity effect of diazepam on [3H]TBOB 
binding is at least partially GABA dependent.
It is likely that the low affinity potency of diazepam to displace 
[3H]TBOB binding has physiological relevance.
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The GABAa receptor complex is a heterogeneous oligomeric protein (1). 
It comprises the Cl'channel as well as binding sites for a variety of compounds, 
e.g binding sites for GABA (gamma-aminobutyric acid), benzodiazepines, bar­
biturates and convulsants (2). All the receptor sites on the complex are al- 
losterically coupled, resulting in a network of interactions ultimately controlling 
the ion channel.
Several interactions have been described: Benzodiazepine agonists 
allosterically enhance the affinity of GABA for its low affinity receptor site 
(3,4,5,6). GABA allosterically displaces TBPS ([35S]t-ButyIbicyclophosphoro- 
thionate) binding to the convulsant sites (7,8). Based on these findings we may 
expect a benzodiazepine effect on the binding of ligands to the convulsant site: 
a potentiation of the displacement by GABA should be found. Yet, conflicting 
data have been published on the effects of benzodiazepines on convulsant 
binding. Benzodiazepine agonists either increased (9,10) or decreased (11,12) 
convulsant binding depending on the amount of GABA present (13). The 
enhancement has been attributed to non-equilibrium conditions of TBPS 
binding (14,15). The displacement of convulsant binding requires micromolar 
concentrations of benzodiazepines, in contrast to the nanomolar affinities of the 
benzodiazepines for their specific binding sites (16,17,18,19).
We conducted a detailed study on the interactions between GABA, 
bicuculline methochloride and diazepam on the binding of the convulsant site 
ligand [3H]-t-butylbicycloorthobenzoate: [3H]TBOB (12,20). As will be seen, 
[3H]TBOB labels a site linked to the GABAa receptor complex. We show that 
diazepam, in the presence of GABA, displaces [3H]TBOB according to a two 
sites model.
MATERIALS AND METHODS
Preparation of the membranes
Female Wistar rats were used, they were bred in our laboratory, their weight 
was 200 ± 20 g. Forebrains were homogenized in 9 volumes 0.32 M sucrose at
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0 °C with a Teflon-glass homogenizer. The homogenate was centrifuged at
1.000 x g for 10 min at 4 °C. The supernatant was decanted and centrifuged at
48.000 x g for 30 min at 4 °C. The pellets were washed two times by suspen­
sion in 50 mM sodium-potassium-phosphate buffer, pH 7.4, containing 500 mM 
NaCl (assay buffer) and centrifugation at 48000 x g for 10 min at 4 °C. The 
pellets were stored at -20 °C until assay. Before assay, the pellets were washed 
once.
Chemicals.
GABA and Bicuculline methochloride were obtained from Sigma Chemical 
Company. Diazepam was a generous gift of Dr. K. Dingelhoff, Roche Neder­
land B.V. [3H]TBOB was obtained from Amersham. The specific activity was 
30 Ci/mmol. Unlabelled TBOB was a generous gift of Dr. C.J. Palmer, Univer­
sity of California, USA.
Assays.
Membrane pellets were homogenized in assay buffer: the tissue concentration 
in incubation medium was 12.5 mg/ml. Into glass tubes we pipetted consecu­
tively: 25 |jl of [3H]TBOB and either drugs or buffer in volumes of 25 |al. The 
final concentration of [3H]TBOB in the incubation mixture was 8 nM. The 
incubation was started by adding 200 |il of tissue homogenate. Incubations were 
performed at 25 °C, lasted 90 min and were terminated by adding 3 ml ice cold 
buffer to the incubation tubes and rapid filtration of the mixture through 
Whatman GF/B filters. The filters were washed two times with 3 ml ice cold 
assay buffer. Radioactivity retained in the filters was counted by liquid scintil­
lation spectrometry. Specific [3H]TBOB binding was defined as total binding 
minus the remaining binding in the presence of 4 |jM TBOB or of 100 jiM 
picrotoxin. Specific binding was 70-75 % of total binding at 8 nM [3H]TBOB. 
Data analysis.
Models were fitted to the data using the nonlinear regression program INPLOT 
to the function of a two sites model:
■® drusr- '® m in +  (  7^  7 T "\ +  — TT\ --------- )
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where [drug] is the concentration of the test drug in moles/1. Bdros is the % 
binding in the presence of the drug of investigation and Bmin is the minimum 
binding in % of control binding. Control binding is defined as [3H]TBOB 
binding in the presence of 10 pM bicuculline methochloride. Bdtng and Bmia were 
determined experimentally. F, is the fraction of binding with an IC50(1), being 0 
for a one site model. (1-FO is the fraction of binding with an IC50(2). KVs are 
the concentrations of the drug that gives half maximum inhibition or enhan­
cement expressed as moles/1, and H’s are the slope factors being positive in 
case of an enhancement and negative in case of an inhibition. The parameters 
that are estimated by non-lineair regression are: Broax, IC50(1), IC50(2), F„ H( 
and H2.
Statistical analysis.
F-tests were used to analyze whether a two site model fits the data better than a 
one site model. Parameters estimates were tested for differences with ANOVA 
followed by Scheffe’s post hoc analysis.
RESULTS
The effect of GABA on r3H!TBOB binding.
The equation given in Materials and Methods was fitted to the data, according 
to a one site model: i.e. F1=0. Results are summarized in table 1 and in fig. 1.
1) GABA displaced all specifically bound [3H]TBOB: The nonspecific binding 
obtained by inhibition of [3H]TBOB with GABA resembled the nonspecific 
binding determined by inhibition with unlabelled TBOB (4 jiM) or picrotoxin 
(100 pM) and was about 30 % of total binding.
2) GABA displaced [3H]TBOB binding with an IC50 of 5.2 pM (value not 
corrected for endogenous GABA).
3) The concentration of endogenous GABA in our samples, determined by 
aminoacid analysis (21) was 2.43 ± 0.13 (iM (mean ± SEM, n=16).
4) Control binding was defined as [3H]TBOB binding in the presence of 10 [iM 
bicuculline methochloride. The binding of [3H]TBOB in the presence of 
endogenous GABA was 63 ± 2 % of control binding (mean ± SEM, n=4).
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TABLE 1
The effect of GABA on the binding of [3H]TBOB in the absence and in the 
presence bicuculline methochloride (BMC).
Drugs present IC50 GABA 
(MM)
Slope 
factor {H)
endogenous GABA 
" + 10 \m  BMC
5.2 ± 0.1 
44 ± 2
1.11 ± 0.02 
1.12 ± 0.05
Parameters estimates obtained by fitting the formula given in Materials and 
Methods to the data. Without addition of bicuculline methochloride: mean ± 
SEM of n=4 in triplicate. In the presence of bicuculline methochloride: cumu­
lated data points of 2 experiments: fit result ± SE of fit. Data are not corrected 
for endogenous GABA. When adjusted for the endogenous GABA content, as 
depicted in fig.l, the IC50 of GABA was 4.0 ± 0.2 |aM.
[3H]TB0B bound (%)
100 -
80-
60-
40-
2 0 -
0 J i i  i i i it ml----1
GABA (M)
Figure 1: The effect of GABA on [3H]TBOB binding in the presence of 2.4 fiM 
endogenous GABA (circles) (data points: mean ± SD, n = 4 in triplicate) and in 
the presence of bicuculline methochloride (10 |iM, triangles, cumulated data of 
n = 2 in triplicate). Endogenous GABA inhibits [3H]TBOB to 63 % of control 
binding (i.e. the binding in the presence of 10 |iM bicuculline methochloride). 
GABA displaces [3H]TBOB according to a one site model. The estimated Bmax 
value was not significantly different from 100 %. Bicuculline methochloride 
shifts the displacement curve of GABA to the right.
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TABLE 2
The effect of bicuculline methochloride (BMC) on the binding of [3H]TBOB in 
the absence and in the presence of GAB A or of diazepam (Dia).
Drugs present
m )
Bmin
(%)
EC50 BMC 
(|IM)
Bmax
<%)
GABA endo 63.9 ± 2.1* 0.52 ± 0.08* 101.5 ± 0.8
GABA endo + GABA 8 19.9 ± 1.7 2 .30 ± 0.21 106.2 ± 3.8
GABA endo + Dia 50 23.4 ± 3.4 1.77 ± 0.26 94.0 ± 2.3*
Parameters estimates obtained by fitting the formula given in Materials and 
Methods to the data. Mean ±  SEM of n = 4 in triplicate. Per column an * 
indicates significant differences, ANOVA, F(2,ll) > 12.6 followed by Scheffe 
post hoc analysis, p<0.05. Slope factors were not different from unity.
[ 3H]TBOB bound (%)
100
80
60
40
20
0
Figure 2: The effect of bicuculline methochloride on [3H]TBQB binding in the 
presence of endogenous GAB A (circles), of (endogenous + 8 pM) GAB A 
(squares), or of (endogenous GABA + 50 pM diazepam) (stars) (data points: 
mean ± SD, n = 4 in triplicate). Bicuculline methochloride reverses the in­
hibitory effect of GABA and that of diazepam.
I I i I fcUuJ , l . „ l  I I mil, I . M M u J
o icrs io-7 1er6 io-5 1er4
BicucullineMCl (M)
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5) After correction for endogenous GABA, GABA was found to displace 
[3H]TBOB binding with an IC50 of 4.0 pM. The estimated value for Bmax was 
108 ± 8 %. This was not significantly different from 100 %.
6) In the presence of 10 pM bicuculline methochloride the displacement curve
of [3H]TBOB by GABA was shifted parallelly to the right.
The effect of bicuculline methochloride on PH1TBOB binding.
The equation was fitted to the data, according to a one site model: i.e. F1=0.
Results are summarized in table 2 and in figure 2.
1) Bicuculline methochloride reversed the inhibitory effect of endogenous 
GABA with an EC50 of 0.5 pM (table 2).
2) In the presence of (endogenous + 8 pM) GABA the binding is 20 % of 
control. Bicuculline methochloride reversed this effect completely with an EC50 
of 2.3 pM.
3) In the presence of endogenous GABA and 50 pM diazepam the binding is 
23 % of control. The nonspecific binding was not influenced by the addition of 
50 pM diazepam. The displacing effect of endogenous GABA and diazepam is 
reversed by bicuculline methochloride with an EC50 of 1.8 pM, to a maximum 
of 94 % of control.
The effect of diazepam on r3H!TBOB binding.
The equation was fitted to the data, results are listed in table 3 and fig. 3.
1) See fig. 3, upper line. In the presence 10 pM bicuculline methochloride, 
diazepam displaced [3H]TBOB to a minimum of 72 ± 4 % at 10'4M (n=4). In a 
one site model an extrapolated ICSQ of 215 pM was found. In order avoid 
extrapolation, we determined the IC10’s as well: In the presence of bicuculline 
methochloride a 10 % displacement was achieved at 24 pM. The highest 
obtainable concentration diazepam was 10~4 M.
2) See fig. 3, lower two lines. Diazepam displaced [3H]TBOB completely in the 
presence GABA. This displacement could best be described by a two-sites 
model (F-tests, p<0.0001).
2.1) [3H]TBOB binding was 63 %. of control in the presence of 2.4 pM 
endogenous GABA. Diazepam displaced [3H]TBOB binding with the following
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TABLE 3
The effect of diazepam on the binding of [3H]TBOB in the absence and the 
presence of bicuculline methochloride or of GABA.
Drug present
(MM)
Bmax
(%>
B {X) 
(%)
IC50(1) 
(ntt)
B (2) 
(%)
IC50(2) 
(JIM)
IC10 {2) 
(JIM)
BicMCl 10 100 # 0 # 100 # 215 ±31 # 24. 5±3 . 5#
GABA endo 62.6±2.2* 10.6±1.9* 65±18* 52.1±1,7* 43.7± 4.5* 10 . 4±1. 0*
GABA endo+4 35.1±2.1§ 8 .1±1.4* 44±18* 26.9±1.80 20 . 9± 1.18 12.9±1 .3*
Parameters estimates obtained by fitting the formula given in Materials and 
Methods to the data. B(l) is the binding with IC50(1) (FjxBmax), B(2) is the 
binding with IC50(2) ((l-F1)KBmax). Mean ± SEM, n=4-6 in triplicate. Per 
column different symbols indicate significant differences; ANOVA, F(2,15) >
11.2, followed by Scheffe post hoc analysis, p<0.05. Slope factors were not 
different from unity.
[ 3 H]TB0B bound  (%)
100
80
60
40
20
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0 1 0 "xo 1CT8 10~6 10" 4
Diazepam (M)
Figure 3: The effect of diazepam on [3H]TBOB binding in the presence of 10 
jiM bicuculline methochloride (upper line, triangles), of endogenous GABA 
(middle line, circles) or of (endogenous + 4 juM) GABA (lower line, squares) 
(data points: mean ± SD, n = 4-6 in triplicate). In the presence of bicuculline 
methochloride, diazepam displaces [3H]TBOB according to a one site model, in 
the presence of GABA, diazepam displaces [3H]TBOB according to a two site 
model.
[3H]TBOB bin d in g  TO GABAa r e c e p t o r  c o m pl e x 795
parameters: 10 % of the binding had an IC50 of 65 nM, while the remaining 53 
%  had an IC50 of 44 (iM. A 10 % of control displacement of the lowest affinity 
site was achieved at 10 pM diazepam.
2.2) [3H]TBOB binding was 35 % of control in the presence of 6.4 (xM GABA. 
Diazepam displaced this binding as follows: 8 % had an IC50 of 44 nM, while 
the remaining 27 % had an IC50 of 21 joM. A 10 % of control displacement of 
the lowest affinity site was achieved at 13 (iM.
DISCUSSION
The present study provides additional evidence that [3H]TBOB, like 
[35S]TBPS, specifically labels a site associated with the GABAA-receptor 
complex (22,23) since i) GABA completely allosterically displaces [3H]TBOB 
and ii) the displacing effect was reversed by the competitive GABAa antagonist 
bicuculline methochloride (24).
The micromolar IC50 value of GABA indicates that the GABA site that 
is allosterically coupled to the convulsant site, is the low affinity one, as was 
reported (8). Bicuculline methochloride shifts the GABA displacement curve 
parallelly to the right. Such a right shift by antagonists is usually observed in 
functional dose-response studies (25). Therefore, the [3H]TBOB receptor 
binding assay can be interpreted in terms of a physiological dose-response 
experiment. Indeed it has been shown that the inhibition of the binding of the 
cage convulsant [35S]TBPS correlates with a physiological parameter namely 
the enhancement of Cl* uptake (26).
Diazepam displaces [3H]TBOB as well. In the presence of micromolar 
concentrations of GABA, the data can be described with a two-sites model with 
nM and |jM affinities. The nM affinity site is not demonstrable when the 
GABA low affinity site is occupied by the antagonist bicuculline methochlor­
ide. This observation confirms that nM concentrations of diazepam displace 
[3H]TBOB indirectly via potentiation of the displacing effect of GABA (3,4). 
Using in vitro receptor binding studies with [3H]muscimol or [3H]diazepam, it
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is well documented that pM concentrations of GAB A enhances the riM affinity 
of diazepam and vice versa (6,17). We show that the [3H]TBOB binding assay 
can be used to demonstrate the interaction between the low affinity site of 
GABA and the high affinity site of diazepam as well. Moreover, parameter 
estimates describing the allosteric interaction between the GABA low affinity 
site and the diazepam high affinity site obtained by [3H]TBOB binding (table 3) 
are in agreement with those obtained by [3H]muscimol binding or [3H]diazepam 
binding (6,17). [3H]TBOB binding revealed an additional interaction between 
the GABAa receptor complex and diazepam. Diazepam displaces [3H]TBOB 
binding with a potency in the micromolar range as well. The displacement of 
[3H]TBOB by pM concentrations of diazepam is found in the presence of 
GABA as well as in the presence of bicuculline methochloride, but the para­
meters estimates differ: the IC50 in the presence of GABA is lower than the 
IC50 in the presence of bicuculline (table 3). Moreover bicuculline reverses not 
only the inhibitory effect of the nM concentrations of diazepam but at least part 
of the effect of pM concentrations diazepam as well (fig. 2, table 2). We 
conclude therefore that GABA modulates the |liM  potency of diazepam to 
displace [3H]TBOB.
The low affinity potency of diazepam can be explained in different 
ways. It may represent an interaction with a specific binding site on the 
GABAa receptor complex or it may reflect an allosteric negative cooperation 
between two interdependent receptor sites on the GABAa complex (25). 
Another possibility is an interaction with a membrane component resulting in a 
secondary interference with the GABAa complex. The presence of specific pM 
affinity sites for benzodiazepines have been described (27,28). Delorenzo (29) 
reported a micromolar benzodiazepine site coupled to Ca2+ channels. Since the 
binding of [3H]TBOB is restricted to GABAa receptors, the pM benzodiazepine 
effect described here is not the result of an interaction with the site described 
by Delorenzo. A pM effect of benzodiazepines related to the convulsant site on 
the GABAa receptor is reported by Gee (28). Micromolar concentrations of the
[3H]TBOB BINDING TO GABAa RECEPTOR COMPLEX 797
convulsant benzodiazepine Ro 5-4864 modulates the convulsant site in a GABA 
dependent manner (28,30,31). No specific Ro 5-4864 binding sites on the 
GABAa complex are characterized yet. The interaction of micromolar con­
centrations of Ro 54864 with the GABA receptor complex is believed to be 
responsible for the proconvulsive action of the compound (32). This proconvul- 
sive action can be blocked by diazepam but not by flumazenil (32), a ben­
zodiazepine antagonist with nM affinity (33). Preliminary results with 
[3H]TBOB binding show that flumazenil (1 jiM) is able to eliminate the 
inhibitory effect of nM concentrations of diazepam but not its micromolar 
effects. Therefore diazepam and Ro 5-4864 might interact with the same low 
affinity site for benzodiazepines on the GABA complex, with opposite effects.
The question remains what is the clinical pharmacological relevance of 
the low affinity benzodiazepine influence? The ability of nanomolar con­
centrations of diazepam to enhance the affinity of GABA is generally held to 
be responsible for the majority of its clinical effects (3,4,34). The slopes of 
functional dose-response curves of benzodiazepines for overall CNS depression 
are less than unity and the EC50 are in the order of |oM (3,35). Fitting our data 
to the equation of a one site model yields a slope factor of 0.6 and an IC50 
value of 15 |iM. The performance of a two site model was significantly better 
and therefore we hypothesize that the slight in vivo slopes camouflage a two 
site model. Recent in vivo data for midazolam support this hypothesis: a two 
phasic dose-response curve on partial convulsive epilepsy was reported (36). 
Flumazenil did not antagonize the anticonvulsant effect of the high doses 
midazolam (36), being in agreement with our preliminary in vitro data. There­
fore it is likely that the low affinity benzodiazepine site found in vitro has 
physiological relevance.
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